Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evaluering av effekten av neothelium FT i behandlingen av kroniske åpne sår

9. november 2026 oppdatert av: NuScience Medical Biologics, LLC

Evaluering av effektiviteten av neothelium FT i helbredelse av kroniske åpne sår: en randomisert kontrollert multisenterstudie

This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.

Studieoversikt

Status

Rekruttering

Forhold

Detaljert beskrivelse

This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will be randomly assigned to one of two groups: either standard of care (SOC) alone, or SOC plus NeoThelium FT.

The study includes a crossover component for subjects in the SOC arm. At treatment visit 13 (approximately 84 days post-randomization), SOC arm subjects not having achieved complete wound closure, and still meeting the inclusion/exclusion criteria, are eligible to cross over to the IP arm (SOC plus NeoThelium FT). Crossover subjects will begin IP arm treatment with weekly NeoThelium FT applications for up to 12 treatment visits. The subject will continue follow-up per the original schedule. As this is a post-marketing study, it will gather information regarding the efficacy of treatment while also supporting insurance reimbursement decisions. All subjects will complete two-week screening phase prior to being randomized into a treatment arm. Treatment arms will consist of NeoThelium FT in conjunction with standard of care, vs. standard of care alone. The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 12 weeks. Secondary endpoints consist of wound percentage area reduction rates and pain assessment.

Studietype

Intervensjonell

Registrering (Antatt)

132

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Angelina Ferguson, DNP
  • Telefonnummer: (985) 629-4013
  • E-post: info@sygnola.com

Studer Kontakt Backup

Studiesteder

    • Louisiana
      • Denham Springs, Louisiana, Forente stater, 70726
        • Rekruttering
        • MedCentris of Denham Springs
        • Hovedetterforsker:
          • Monique Consoer, NP
        • Ta kontakt med:
      • Hammond, Louisiana, Forente stater, 70403
      • Lafayette, Louisiana, Forente stater, 70507
        • Fullført
        • MedCentris of Carencro
      • Leesville, Louisiana, Forente stater, 71146
        • Rekruttering
        • MedCentris of Leesville
        • Hovedetterforsker:
          • Stefanie Corley, FNP
        • Ta kontakt med:
      • Many, Louisiana, Forente stater, 71449
        • Rekruttering
        • MedCentris of Many
        • Hovedetterforsker:
          • Stefanie Corley, FNP
        • Ta kontakt med:
      • Marksville, Louisiana, Forente stater, 71351
      • Metairie, Louisiana, Forente stater, 70001
        • Rekruttering
        • MedCentris of Metairie
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sarah Logrande, NP
      • Minden, Louisiana, Forente stater, 71055
      • Monroe, Louisiana, Forente stater, 71201
        • Har ikke rekruttert ennå
        • MedCentris of Monroe
        • Hovedetterforsker:
          • Libbi Trawick, NP
        • Ta kontakt med:
      • Slidell, Louisiana, Forente stater, 70458
        • Rekruttering
        • MedCentris of Slidell
        • Hovedetterforsker:
          • Katie Schloegel, FNP
        • Ta kontakt med:
    • Mississippi
      • D'Iberville, Mississippi, Forente stater, 39540
        • Fullført
        • MedCentris of D'iberville
      • McComb, Mississippi, Forente stater, 39648
        • Fullført
        • MedCentris of McComb
      • Natchez, Mississippi, Forente stater, 39120
        • Fullført
        • MedCentris of Natchez
      • Southaven, Mississippi, Forente stater, 38671
        • Rekruttering
        • MedCentris of Southaven
        • Hovedetterforsker:
          • Carlene McAllister, NP
        • Ta kontakt med:
    • New York
      • Brooklyn, New York, Forente stater, 11234
        • Rekruttering
        • Northeast Podiatry Consultant
        • Ta kontakt med:
        • Hovedetterforsker:
          • David Simon, DPM, FACFAS

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or Female, 18 years of age or older
  2. Subject has a medical diagnosis of "other" Open wound
  3. Subject has a chronic open wound present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
  4. Subject has a chronic open wound with a historical wound measurement showing less than 25% healing within 14 days prior to screening
  5. Subject has a chronic open wound with screening wound measurement showing less than 25% healing within 14 days prior to randomization
  6. Subject has an Open wound without infection or clinically visible exposed bone
  7. Index wound is a minimum of 0.5cm2 and a maximum of 25cm2 at first treatment visit
  8. Index ulcer has a maximum depth of 1cm at screening visit 1
  9. The chronic open wound is treated with offloading therapy, if applicable to location, while standing, sitting, and lying down for 14 days prior to randomization
  10. Adequate circulation of wounds located below the knee demonstrated by an ABI of >0.7 and <1.3, or TBI of >0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization.
  11. Index ulcer is free of infection prior to randomization and during screening phase.
  12. Index ulcer is free of necrotic debris prior to NeoThelium FT application
  13. Female subjects of childbearing potential having a negative pregnancy test prior to randomization
  14. Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
  15. Subject is able and willing to follow the protocol requirements
  16. Subject had signed informed consent
  17. If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm

Exclusion Criteria:

  1. Subject with a wound diagnosis of diabetic foot wound, pressure wound, venous leg wound, burn wound, or alternative diagnosis other than "open wound"
  2. Subject has a known life expectancy of <1 year
  3. Subject is unable to comply with protocol treatment
  4. Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing.
  5. Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
  6. Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
  7. Known contraindications to tissue-engineered allograft
  8. Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing
  9. Subject is pregnant or breastfeeding
  10. Subject with history of immunosuppressant treatment (systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for >2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
  11. Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
  12. Open wound with active infection
  13. Wound depth with visible exposed bone
  14. HBOT within 14 days prior to randomization
  15. Revascularization surgery on the index wound leg within 30 days of screening phase
  16. Index wound suspicious of neoplasm in the opinion of the principal investigator

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: No Intervention: Standard of Care

Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading

Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading

Eksperimentell: Intervention: NeoThelium FT & Standard of Care

Wound cleansing, sharps debridement, NeoThelium FT application, Dressing for moisture balance, Offloading

NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Complete Wound Closure
Tidsramme: 1-12 weeks

The primary endpoint will be the percentage of target ulcers that achieve complete wound closure.

1-12 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage Wound Area Change
Tidsramme: 1-12 weeks

The percentage change in wound area from TV-1 to TV-13 will be measured weekly using digital photographic planimetry and physical examination.

1-12 weeks
Pain Assessment
Tidsramme: Day 0, Day 14, Day 35, Day 56, Day 84

Change in pain associated with the target ulcer will be assessed using the Numeric Pain Rating Scale at designated time points

Day 0, Day 14, Day 35, Day 56, Day 84

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Follow-Up Closure
Tidsramme: 2 weeks

Number of wounds remaining closed during the 2-week follow-up

2 weeks
Adverse Events and Serious Adverse Events
Tidsramme: Day -14 through 91 days

The number and nature of adverse events (AEs) and series adverse events (SAEs) occurring during the study will be tracked and reported.

Day -14 through 91 days
Time to Closure
Tidsramme: 1-12 weeks

Average number of grafts and/or weeks used to achieve wound closure

1-12 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Studieleder: Angelina Ferguson, DNP, SygNola, LLC

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

16. oktober 2025

Primær fullføring (Antatt)

31. desember 2027

Studiet fullført (Antatt)

30. januar 2028

Datoer for studieregistrering

Først innsendt

31. mars 2025

Først innsendt som oppfylte QC-kriteriene

8. april 2025

Først lagt ut (Faktiske)

9. april 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere